• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

About FDA

  • Print
  • Share
  • E-mail

CVM Annual Report FY2011 - Table of Contents

2011 CVM Annual Report

TABLE OF CONTENTS

  

INTRODUCTION

 

LEADERSHIP


A Message from the Center Leadership
 

WHAT’S NEW & INNOVATIVE?
 

  • World Veterinary Year
  • Food Safety Modernization Act
  • FDA Foods and Veterinary Medicine Strategic Plan: 2012–2012
  • Improving Efficiency and Effectiveness trough Electronic Submissions: Innovation in the Pre-Approval and Post-Approval Spheres
  • Innovative Mechanisms for Responding to Pet Food and Animal Feed Safety Issues
  • Unapproved New Animal Drug Initiative
  • CVM’s “Best Practice” Strategic Human Capital Plan 2012–2016
 

CHALLENGES & ACCOMPLISHMENTS


Increasing the Supply of Safe and Effective Drugs
  • Significant Approvals
  • Innovative Approaches to Facilitate Approval
  • Other Approaches to Facilitate Approvals
  • Target Animal Safety and Effectiveness Protocol Development and Submission – Guidance for Industry #215
 
Increasing Drug Availability for Minor Use and Minor Species (MUMS)
  • Designations
  • Indexing
  • Conditional Approvals
  • Liaison to the U S Department of Agriculture’s (USDA’s) Minor Use Animal Drug Program
  • Guidance for Industry
 
Antimicrobial Resistance
  • Antimicrobial Drug Marketing Data
  • Judicious Use of Medically Important Antimicrobial Drugs
  • Changing the Marketing Status of Medically Important Antimicrobials
  • Cephalosporin Extra label Use
  • Medical Countermeasures
  • Antibiotic Residue in Distillers Grains
 
Using the National Antimicrobial Resistance Monitoring System to Obtain Critical Information
  • National Antimicrobial Resistance Monitoring System (NARMS) Strategic Plan: 2012-2016
  • A NARMS Success Story
  • Prevalence of Methicillin-Resistant Staphylococcus Aureus (MRSA) and Vancomycin-Resistant Enterococci (VRE)
  • Expansion of NARMS Activities
  • NARMS Reports
 
Avoiding Unsafe Drug Residues in Human Food
  • Enforcement Actions
  • Focus on Dairy Farms
  • Dairy Farm Injunction
  • Calf Dealer Injunction
  • Mental Modeling – Dairy Farmers
  • Suspension of the Sale of Roxarsone
  • Import Tolerances
  • Research Related to the Detection of Drug Residues
 
Ensuring Feed Safety
  • The Major Impact of the Food Safety Modernization Act
  • Preventative Controls to Avoid Contamination and Other Problems  
  • Effective Agency Response to Unsafe Products
  • User Fees
  • Generally Recognized as Safe (GRAS) Voluntary Notification Initiative
  • Bovine Spongiform Encephalopathy (BSE)/Feed Safety Support Program Grants
 
Biotechnology
  • Introduction
  • The Animal Biotechnology Interdisciplinary Group’s Achievements in FY 2011
 
Surveillance and Compliance Actions that Protect Public and  Animal Health
  • Pharmacovigilance
  • Adverse Drug Experience (ADE) Reports
  • Electronic Standards for Transfer of Data
  • Drug Shortages
  • Product Warnings
  • Working with the Coordinated Outbreak Response and Evaluation Network
  • Recalls
  • Regulation of Pet Food
  • Other Compliance Actions
 
Enhancing Productivity through Achievement of Leadership and Management Objectives
  • Planning for Strategic Use of Resources
  • Enhancing Operational Effectiveness of the Foods Program
  • Creativity and Innovation in Workforce Development
 
Expanding International Outreach
  • CVM’s International Programs Strategic Plan: 2011-2015
  • World Organization for Animal Health (OIE) Collaborating Centre
  • CVM’s Participation in Bilateral and Trilateral Meetings
  • Leadership and Innovation in the International Arena
  • CVM Training Presentations and Travel for International Events    
  • CVM Meetings with Foreign Officials
  • Sanitary/Phytosanitary Notifications
 
Communicating With Stakeholders
  • Exhibit Programs
  • Website Enhancements
 
Science at CVM
  • Ensuring Safety of Drugs in Food Animals
  • Innovative Models and Approaches to Evaluating Drug Efficacy
  • Nanotechnology
 

APPENDICES

  • About CVM   
  • Significant Regulations, Guidances, and Other Documents
  • Significant New Animal Drug Approvals
  • Publications   
 
(This report describes the Center’s activities as of the end of Fiscal Year 2011 [September 30, 2011] We  anticipated that most readers will review this report not  long after the end of FY 2011  Therefore, we use language such as “now” and “CVM is planning,” based on the assumption that the reader will understand that the information presented in the report was current when the report was published)
 

Top

Next>>